Healthcare / Drug Manufacturers - Specialty & GenericMilan
$130.80
-0.15 (-0.11%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $2.0B · quality 77.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$56.9B
P/E
22.5x
↑EV/EBITDA
11.1x
↓ROE
9.1%
↑Gross Margin
58.5%
↑Debt/Equity
0.42
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-1.7%
FCF CAGR
-7.0%
FCF margin
9.4%
FCF / Net income
0.76x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $21.10B · net income $2.61B · FCF $1.97B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $21.10B | $21.10B | $21.16B | $20.99B | $22.23B |
| Net Income | $2.61B | $2.61B | $2.78B | $2.82B | $3.33B |
| EBITDA | $5.99B | $5.99B | $5.96B | $5.68B | $6.55B |
| EPS | 6.00 | 6.00 | 6.39 | 6.49 | 7.65 |
| Gross Margin | 58.5% | 58.5% | 59.0% | 59.0% | 61.6% |
| Operating Margin | 17.3% | 17.3% | 18.9% | 17.0% | 21.4% |
| Net Margin | 12.4% | 12.4% | 13.1% | 13.5% | 15.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.42 | 0.42 | 0.34 | 0.37 | 0.40 |
| Current Ratio | 1.51 | 1.51 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.97B | $1.97B | $2.40B | $1.76B | $2.45B |
| Returns | |||||
| ROE | 9.1% | 9.1% | 9.3% | 10.6% | 12.8% |
| Valuation | |||||
| P/E | 22.47 | 22.47 | 21.96 | 22.06 | 24.12 |
| EV/EBITDA | 11.10 | 11.10 | 11.59 | 12.41 | 13.62 |
| P/B | 1.99 | 1.99 | 2.04 | 2.33 | 3.09 |
| Growth & Yield | |||||
| Revenue Growth | -0.3% | -0.3% | 0.8% | -5.6% | — |
| EPS Growth | -6.1% | -6.1% | -1.5% | -15.2% | — |
| Dividend Yield | 1.7% | 1.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
24.6%
EPS terminal req.
$11.61
Spread vs growth
-30.7%
5Y implied EPS CAGR
18.5%
EPS terminal req.
$14.04
Spread vs growth
-24.6%
10Y implied EPS CAGR
14.2%
EPS terminal req.
$22.62
Spread vs growth
-20.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+14.2%
Start / end P/E
18.2x → 21.8x
EPS bridge
6.39 → 6.00
Residual
-1.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.